Crossmark

A timely recommendation to the european medicines agency and the FDA on rationalizing comparative clinical efficacy testing of biosimilars

Published Online: 2024-10-28

Authors

Niazi, Sarfaraz K.
License Information

Text and Data Mining valid from 2024-10-28

Version of Record valid from 2024-10-28
More Information

Article History

Received: 8 May 2024

Accepted: 14 October 2024

First Online: 28 October 2024

Declarations

:

: Not applicable.

: Not Applicable.

: The author is a developer of biosimilars and advisor to FDA, EMA and MHRA.

Document is current